Navigation Links
Leading Vaccine Expert Joins IAVI
Date:7/3/2008

NEW YORK, July 3 /PRNewswire-USNewswire/ -- Dr. Thomas Hassell, former global vice president of process development at sanofi pasteur, a leading vaccine company, has joined IAVI as vice president for vaccine development. In his new role, Dr. Hassell will lead IAVI's product development efforts that are aimed at rapidly advancing promising vaccine candidates that emerge from the organization's vaccine discovery programs.

Dr. Hassell is trained as a microbiologist and received his Ph.D. at Manchester Metropolitan University in the United Kingdom in 1987. He completed his post-doctorate program at the Massachusetts Institute of Technology as a Rockefeller Foundation Fellow in 1989. He has 20 years of experience within industry, working for several leading vaccine developers taking early-stage vaccine candidates all the way through to licensure.

"If we are to defeat AIDS once and for all, we need a vaccine. To develop a vaccine, we need to translate promising concepts into candidates that are tested in humans. My job at IAVI is to make this happen as quickly and safely as possible," said Dr. Hassell.

At sanofi pasteur, Dr. Hassell led a team of 250 researchers who developed vaccines that have been licensed worldwide. Most recently, Dr. Hassell assisted in the national licensure of Pentacel, a childhood combination vaccine that protects against diphtheria, tetanus, whooping cough, Haemophilus Influenzae Type B, and polio, and Menactra, the first conjugate vaccine to provide protection against four strains, A,C,Y and W, of bacterial meningitis. Dr. Hassell also oversaw the launch of a series of new, state-of-the-art vaccine development facilities in Canada, France and the United States that have enabled sanofi pasteur to better support their existing vaccine portfolio, as well as to allow more rapid development of their new vaccines.

After a vaccine candidate proves promising in pre-clinical animal studies, many steps are required to translate that concept into a vaccine that can be tested in humans and ultimately produced on a large scale for late-stage testing and ultimately licensure. Dr. Hassell comes from one of very few companies that has the expertise to research, develop, license, manufacture and distribute new vaccines. This experience will help IAVI to rapidly bring promising concepts that emerge from its AIDS Vaccine Development Laboratory into the clinic for testing in humans.

To date, there have only been two AIDS vaccine candidates that have been fully tested, and both have failed in efficacy trials. With 2.5 million people becoming newly infected with HIV each year, there is an urgent need to develop and rapidly advance promising vaccine candidates into testing to accelerate the development of an effective AIDS vaccine. IAVI created its AIDS Vaccine Development Laboratory to systematically test novel vaccine vectors and promising antigens that will ultimately form the foundation of the next generation of AIDS vaccine candidates. Dr. Hassell will work to ensure that these promising vaccine approaches are successfully translated into viable vaccine candidates for testing.

About IAVI

The International AIDS Vaccine Initiative (IAVI) is a global not-for-profit organization whose mission is to ensure the development of safe, effective, accessible, preventive HIV vaccines for use throughout the world. Founded in 1996 and operational in 24 countries, IAVI and its network of collaborators research and develop vaccine candidates. IAVI's financial and in-kind supporters include the Alfred P. Sloan Foundation, the Bill & Melinda Gates Foundation, the Foundation for the National Institutes of Health, The John D. Evans Foundation, The New York Community Trust, the James B. Pendleton Charitable Trust, The Rockefeller Foundation, The William and Flora Hewlett Foundation; the Governments of Canada, Denmark, Ireland, The Netherlands, Norway, Spain, Sweden, the United Kingdom, and the United States, the Basque Autonomous Government as well as the European Union; multilateral organizations such as The World Bank; corporate donors including BD (Becton, Dickinson & Co.), Bristol-Myers Squibb, Continental Airlines, Google Inc., Henry Schein, Inc., Merck & Co., Inc. and Pfizer Inc; leading AIDS charities such as Broadway Cares/Equity Fights AIDS and Until There's A Cure Foundation; other private donors such as The Haas Trusts; and many generous individuals from around the world. For more information, see http://www.iavi.org.


'/>"/>
SOURCE International AIDS Vaccine Initiative
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Leading Eating Disorder Treatment Center Identifies Popular Diet Myths
2. Chinas Leading Healthcare Market Player Records 200% Increase in Profits and Earnings
3. Leading Provider of Electronic Medical Records (EMR) Systems for Sleep Centers Adds Field Sales Representative
4. Leading Performance-Enhancing Drug Research Institute Anti-Doping Research (ADR) Establishes Nonprofit Status
5. Leading Fertility Center Adds New Physician
6. Leading Healthcare Organizations Overwhelmingly Select Sentillion for User Provisioning
7. Long-term safety data on Lialda published in leading GI journal
8. Long-Term Safety Data on Lialda(TM) (mesalamine) for Patients With Ulcerative Colitis Published in Leading GI Journal
9. DrScore, the Premier Online Patient Satisfaction Service Partners With Leading Healthcare Web Design Firm, Practis, Inc.
10. PartsSource Given 2008 Leading Edge Award for Second Straight Year
11. Front Line Caregiver Coalition Thanks Sens. Conrad, Coleman and Reps. Pomeroy, Capito and Berkley for Leading Bipartisan Hill Effort to Stop Bush Administrations Damaging Medicare Cuts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... International Protein, ... nutritional and bodybuilding supplements, announced it attended the January ECRM trade show in Hilton ... and nutritional scientist who was determined to create a line of products that would ...
(Date:1/20/2017)... ... , ... “Mary Magdalene: Grace is Greater than Sin”: a unique and ... Christ firsthand. “Mary Magdalene: Grace is Greater than Sin” is the creation of published ... with countless women who had little knowledge of the female characters portrayed in the ...
(Date:1/20/2017)... Farmville, NC (PRWEB) , ... January 20, 2017 ... ... the vPEP ® Oscillating Positive Expiratory Pressure (OPEP) device, was featured in ... article by Doug Pursley, MEd, RRT-ACCS, FAARC, “Analysis of Three Oscillating Positive ...
(Date:1/20/2017)... ... 20, 2017 , ... “The Land of More and More”: a brilliant ... hunger, and shares the simple and achievable answer. “The Land of More and More” ... Fairview Missionary Church in Angola, Indiana where he works with the children’s ministry department. ...
(Date:1/19/2017)... ... 19, 2017 , ... Next week after January 20th, the fear for many ... that circumvent health needs of over 30 million. Many interviews with Dr. Carol Francis ... government public servants were suppose to prioritize. Interviews provided below. , Among ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... YORK , Jan. 19, 2017 This ... the current and future scenario of the global market. ... rising opioid consumption. Severe chronic constipation is a major ... to traditional laxatives. Hence, novel targeted therapy has been ... OIC sufferers, launch of targeted medicines, and growing awareness ...
(Date:1/19/2017)... 19, 2017  Stealth BioTherapeutics Inc. ( Stealth ), ... dysfunction, today announced new additions to its senior leadership ... Medical Officer, and Daniel Geffken as interim ... Jim Carr , Pharm.D. has been promoted to Chief ... to welcome Doug and Daniel to our management team, ...
(Date:1/19/2017)... January 19, 2017 According to a study ... is set to witness a CAGR of 6.5% during the forecast ... will continue to be the leading market for cryotherapy globally ... ... emphasizing on ensuring affordable and adequate supply of gas in order ...
Breaking Medicine Technology: